Corporate Investor

Updated:

Beijing Beilu Pharmaceutical

Beijing Beilu Pharmaceutical was established in 1992 by Wang Weidong. Xu Wang serves as current Chairman and General Manager. The firm developed from...

Beijing Beilu Pharmaceutical logo

Beijing Beilu Pharmaceutical

Beijing Beilu Pharmaceutical was established in 1992 by Wang Weidong. Xu Wang serves as current Chairman and General Manager. The firm developed from pharmaceutical manufacturing into a corporate investor structure. The company allocates across an Industry Buyout Fund and direct holdings. Confirmed co-investors include Chongqing Sanxia Paints Co., Ltd. at 6.12 percent and China Resources YuKang Asset Management Co., Ltd. at 2.66 percent. Geographic reach centers on China with production sites in Beijing, Hebei Province and Zhejiang Province. No recent operational events from the last 24 months appear in available records. The firm maintains three dedicated production facilities and headquarters in Haidian District, Beijing. It holds recognition from Beijing municipal lists for private enterprise growth and social responsibility. Ownership remains tied to the founding operator and listed corporate shareholders rather than external limited partners.

General information

Firm type

Corporate Investor

Year founded

1992

AUM

Undisclosed

Location

Region

Asia

Country

China

City

Beijing

Corporate office

Maples International Office Block A, 7th Floor, No. 32 Xizhimen North Street, Haidian District, Beijing, 100082, China

Principals

Wang Weidong

Founder

Xu Wang

Chairman and General Manager

Sector focus

Healthcare Services

Frequently asked questions

Who runs investment decisions at Beijing Beilu Pharmaceutical?

Xu Wang holds the role of Chairman and General Manager. Wang Weidong founded the firm in 1992.

Does Beijing Beilu Pharmaceutical participate in fund commitments or only direct deals?

The firm maintains an Industry Buyout Fund based in Beijing. It also holds direct equity positions through named co-investors.

Where does the underlying wealth come from?

Wealth originates from pharmaceutical product development, production and sales. The company listed on the Shenzhen Stock Exchange in 2009.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Beijing Corporate Investor profiles